Experimental Parkinson's drug talineuren put to early safety test
Disease control
Terminated
This early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be d…
Phase: PHASE1 • Sponsor: InnoMedica Schweiz AG • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC